BR112015006051A2 - usos inéditos - Google Patents

usos inéditos

Info

Publication number
BR112015006051A2
BR112015006051A2 BR112015006051A BR112015006051A BR112015006051A2 BR 112015006051 A2 BR112015006051 A2 BR 112015006051A2 BR 112015006051 A BR112015006051 A BR 112015006051A BR 112015006051 A BR112015006051 A BR 112015006051A BR 112015006051 A2 BR112015006051 A2 BR 112015006051A2
Authority
BR
Brazil
Prior art keywords
unpublished
pruritus
abstract
combinations
compound
Prior art date
Application number
BR112015006051A
Other languages
English (en)
Inventor
Emiliangelo Ratti
Michael Trower
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of BR112015006051A2 publication Critical patent/BR112015006051A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “usos inéditos” esta invenção diz respeito ao uso inédito do composto (i) ou sais farmaceuticamente aceitáveis deste e composições farmacêuticas contendo-os para o tratamento de prurite e às combinações para um uso como este.
BR112015006051A 2012-10-11 2013-10-09 usos inéditos BR112015006051A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712499P 2012-10-11 2012-10-11
PCT/EP2013/071093 WO2014057003A1 (en) 2012-10-11 2013-10-09 Novel uses

Publications (1)

Publication Number Publication Date
BR112015006051A2 true BR112015006051A2 (pt) 2017-07-04

Family

ID=49322388

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006051A BR112015006051A2 (pt) 2012-10-11 2013-10-09 usos inéditos

Country Status (24)

Country Link
US (3) US9603849B2 (pt)
EP (2) EP3597192A1 (pt)
JP (2) JP6815728B2 (pt)
KR (1) KR102202481B1 (pt)
CN (1) CN104703603A (pt)
AU (1) AU2013328695B9 (pt)
BR (1) BR112015006051A2 (pt)
CA (1) CA2884454C (pt)
CY (1) CY1122313T1 (pt)
DK (1) DK2906219T3 (pt)
EA (1) EA201590364A1 (pt)
ES (1) ES2750662T3 (pt)
HK (1) HK1211486A1 (pt)
HR (1) HRP20191955T1 (pt)
HU (1) HUE046508T2 (pt)
IL (1) IL237636B (pt)
LT (1) LT2906219T (pt)
MX (1) MX362879B (pt)
PL (1) PL2906219T3 (pt)
PT (1) PT2906219T (pt)
RS (1) RS59470B1 (pt)
SG (1) SG11201501867UA (pt)
SI (1) SI2906219T1 (pt)
WO (1) WO2014057003A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362879B (es) * 2012-10-11 2019-02-21 Nerre Therapeutics Ltd Usos novedosos.
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2017118584A1 (en) * 2016-01-08 2017-07-13 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough
JP2019519592A (ja) * 2016-06-29 2019-07-11 メンロ セラピューティクス インコーポレイテッド 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用
US11957669B2 (en) 2017-08-11 2024-04-16 Amorepacific Corporation Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
MX2022002646A (es) 2019-09-05 2022-04-26 Incyte Corp Formulacion de ruxolitinib para la reduccion de comezon en dermatitis atopica.
JP7478895B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤
JP7478894B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2728265A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
EP1295599A1 (en) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ　グループ　リミテッド 機能性消化不良を治療するための化学化合物の使用
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
ES2570853T3 (es) * 2007-12-07 2016-05-20 Zymogenetics Inc Moléculas de anticuerpo humanizadas específicas para IL-31
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
JP5425229B2 (ja) * 2009-02-24 2014-02-26 ノバルティス アーゲー Ｎｋ受容体アンタゴニストの使用
EP2683376B1 (en) * 2011-03-07 2018-11-28 Celgene Corporation Methods for treating diseases using isoindoline compounds
AU2013224181A1 (en) 2012-02-22 2014-10-02 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds
MX362879B (es) * 2012-10-11 2019-02-21 Nerre Therapeutics Ltd Usos novedosos.
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus

Also Published As

Publication number Publication date
JP6815728B2 (ja) 2021-01-20
SI2906219T1 (sl) 2019-12-31
EP3597192A1 (en) 2020-01-22
HRP20191955T1 (hr) 2020-01-24
US20170143711A1 (en) 2017-05-25
IL237636B (en) 2019-01-31
AU2013328695A9 (en) 2018-04-26
KR102202481B1 (ko) 2021-01-12
AU2013328695A1 (en) 2015-04-02
EP2906219A1 (en) 2015-08-19
KR20150064732A (ko) 2015-06-11
DK2906219T3 (da) 2019-10-28
US20190216806A1 (en) 2019-07-18
PT2906219T (pt) 2019-11-04
SG11201501867UA (en) 2015-04-29
RS59470B1 (sr) 2019-11-29
AU2013328695B2 (en) 2018-04-05
EP2906219B1 (en) 2019-08-07
US9603849B2 (en) 2017-03-28
HK1211486A1 (en) 2016-05-27
WO2014057003A1 (en) 2014-04-17
JP6953468B2 (ja) 2021-10-27
IL237636A0 (en) 2015-04-30
CY1122313T1 (el) 2021-01-27
CN104703603A (zh) 2015-06-10
MX362879B (es) 2019-02-21
ES2750662T3 (es) 2020-03-26
HUE046508T2 (hu) 2020-03-30
AU2013328695B9 (en) 2018-05-17
US20150238486A1 (en) 2015-08-27
JP2019131594A (ja) 2019-08-08
LT2906219T (lt) 2019-10-25
CA2884454A1 (en) 2014-04-17
JP2015533136A (ja) 2015-11-19
PL2906219T3 (pl) 2020-02-28
CA2884454C (en) 2021-07-27
MX2015004162A (es) 2015-07-06
EA201590364A1 (ru) 2015-11-30

Similar Documents

Publication Publication Date Title
BR112015006051A2 (pt) usos inéditos
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
NI201500167A (es) Compuestos químicos
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
EA201400986A1 (ru) Фармацевтические композиции, содержащие метформин и ингибитор dpp-4 или ингибитор sglt-2
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR102015032361A8 (pt) Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
BR112019003932A2 (pt) composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
CR20130487A (es) 1,3-oxazinas como inhibidores de BACE1 y/o BACE2
BR112014030386A8 (pt) Compostos e composições para modular a atividade de egfr
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
NI201500096A (es) Compuesto químicos
CR20130602A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
BR112017006085A2 (pt) compostos 1-alquil-6-oxo-1,6-di-hidropiridin-3-ila e uso como moduladores sgrm
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]